(Reuters) -U.S. drugmaker Pfizer launched a new multi-year program to reduce its expenses by about $1.5 billion by the end of 2027, adding on to a $4 billion cost cutting plan it announced last year.
The cost cuts are the latest move by the company to respond to slumping demand for its COVID-19 products after they powered it to report record revenues in 2021 and 2022.
Pfizer’s shares were up 2.6% at $29.3 in afternoon trading.
The company said it would record one-time charges, mainly related to severance and implementation costs, of $1.7 billion as part of the new program. It expects to record a majority of the charges this year.
The focus will be on “operational efficiencies, network structure changes, and product portfolio enhancements,” the company said.
(Reporting by Bhanvi Satija in Bengaluru; Editing by Sriraj Kalluvila)
EMEA Tribune is not involved in this news article, it is taken from our partners and or from the News Agencies. Copyright and Credit go to the News Agencies, email news@emeatribune.com Follow our WhatsApp verified Channel
